Literature DB >> 19235776

Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study.

Puja R Myles1, Richard B Hubbard, Tricia M McKeever, Zara Pogson, Christopher J P Smith, Jack E Gibson.   

Abstract

PURPOSE: Previous studies have shown that treatment with gastric acid suppressants may be associated with an increased risk of pneumonia whilst the use of statins and ACE inhibitors (ACEI) may decrease the risk of acquiring pneumonia. The evidence is conflicting however. Our aim was to investigate the effect of these drugs on pneumonia using population-based data from the UK.
METHODS: We conducted a general population-based case-control study using the health improvement network (THIN), a comprehensive UK general practice database. Conditional multiple logistic regression was used to assess the association between the exposures and pneumonia.
RESULTS: After adjusting for potential confounders, a current prescription for statins was associated with a significant reduction in the risk of pneumonia (adjusted OR 0.78, 95% CI 0.65-0.94). Similarly, a current prescription for ACEI was associated with a reduction in the risk of pneumonia (adjusted OR 0.75, 95% CI 0.65-0.86). Contrary to previous study results we did not find a significant association between current prescription for histamine 2 receptor antagonist (H(2)RA) and pneumonia risk (adjusted OR 1.14, 95% CI 0.92-1.40) but current prescriptions for proton pump inhibitors (PPI) were associated with an increased risk of pneumonia (adjusted OR 1.55, 95% CI 1.38-1.77).
CONCLUSIONS: Statins and ACE inhibitors were associated with a lower risk of pneumonia but these effects were smaller than those observed in previous studies. People prescribed a PPI, but not an H(2)RA at an increased risk of acquiring pneumonia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235776     DOI: 10.1002/pds.1715

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  43 in total

Review 1.  Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies.

Authors:  Chun Shing Kwok; Jessica Ka-Yan Yeong; Richard M Turner; Rodrigo Cavallazzi; Sonal Singh; Yoon Kong Loke
Journal:  Eur J Clin Pharmacol       Date:  2011-11-15       Impact factor: 2.953

Review 2.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

3.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

4.  Temporal and within practice variability in the health improvement network.

Authors:  Kevin Haynes; Warren B Bilker; Tom R Tenhave; Brian L Strom; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-13       Impact factor: 2.890

Review 5.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

6.  Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults.

Authors:  Filippo Ansaldi; Andrea Orsi; Cecilia Trucchi; Daniela De Florentiis; Antonella Ceravolo; Martina Coppelli; Sergio Schiaffino; Valter Turello; Roberto Rosselli; Roberto Carloni; Giancarlo Icardi; Ligurian Pneumococcal Study Group; Paola Canepa; Laura Sticchi; Roberta Zanetti; Ilaria Cremonesi; PierClaudio Brasesco; Paolo Moscatelli
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Recurrent pneumonia: a review with focus on clinical epidemiology and modifiable risk factors in elderly patients.

Authors:  T T Dang; S R Majumdar; T J Marrie; D T Eurich
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 3.923

8.  The effect of statin therapy on the incidence of infections: a retrospective cohort analysis.

Authors:  John P Magulick; Christopher R Frei; Sayed K Ali; Eric M Mortensen; Mary Jo Pugh; Christine U Oramasionwu; Kelly R Daniels; Ishak A Mansi
Journal:  Am J Med Sci       Date:  2014-03       Impact factor: 2.378

Review 9.  Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis.

Authors:  Linda Björkhem-Bergman; Peter Bergman; Jan Andersson; Jonatan D Lindh
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

10.  Pharmacotherapy and the risk for community-acquired pneumonia.

Authors:  Jen-Tzer Gau; Utkarsh Acharya; Salman Khan; Victor Heh; Lona Mody; Tzu-Cheg Kao
Journal:  BMC Geriatr       Date:  2010-07-06       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.